Validation study develops a myeloma-specific comorbidity index, suggesting improved treatment decisions in real-world cohorts.
The MM-CI provides a simple, objective, and clinically applicable tool for comorbidity-based risk stratification in MM. It outperforms existing models and may support treatment decisions in real-world practice.
No takes yet. Share an insight, caveat, or question.
Choi et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: